There are several exciting things happening in new treatments for AML. We saw many studies at this meeting with those agents, and I think that in a year or 2 the data will mature to the point where they are going to start contributing to improving outcomes in AML, which is very good news for patients.
Saturday, January 10, 2009
AML and Potential Ways to Gain More Time
The combination of HU, azacitdine and GO appears to be a safe and effective regimen in the treatment of AML and high risk MDS in the elderly.
Older, less fit patients have a poor outcome, and few trials have been conducted in this patient group. Low-dose ara-C treatment was superior to best supportive care and hydroxyurea because it had greater success in achieving CR, and it could represent standard care against which new treatments may be compared in this patient group.
Overall, our study showed that low-dose cytosine arabinoside given by continuous infusion together with continuous infusion GM-CSF and hydroxyurea was well-tolerated and effective in treating elderly AML and MDS patients who were not eligible for standard induction therapy.
GM-CSF priming can enhance the cytoreductive effects of low doses of cytarabine. This combination therapy is well tolerated, and should be explored as an alternative regimen for high risk and elderly AML and advanced MDS patients.
Low-Dose Cytarabine Improves Survival of Older Patients with Leukemia
FYI, This article above is from 2005